全文获取类型
收费全文 | 12941篇 |
免费 | 1246篇 |
国内免费 | 323篇 |
专业分类
耳鼻咽喉 | 172篇 |
儿科学 | 421篇 |
妇产科学 | 153篇 |
基础医学 | 1662篇 |
口腔科学 | 463篇 |
临床医学 | 789篇 |
内科学 | 1715篇 |
皮肤病学 | 69篇 |
神经病学 | 1878篇 |
特种医学 | 415篇 |
外国民族医学 | 3篇 |
外科学 | 1675篇 |
综合类 | 1052篇 |
现状与发展 | 2篇 |
预防医学 | 269篇 |
眼科学 | 2608篇 |
药学 | 505篇 |
2篇 | |
中国医学 | 232篇 |
肿瘤学 | 425篇 |
出版年
2024年 | 24篇 |
2023年 | 220篇 |
2022年 | 280篇 |
2021年 | 489篇 |
2020年 | 534篇 |
2019年 | 507篇 |
2018年 | 529篇 |
2017年 | 503篇 |
2016年 | 490篇 |
2015年 | 480篇 |
2014年 | 750篇 |
2013年 | 1007篇 |
2012年 | 592篇 |
2011年 | 653篇 |
2010年 | 566篇 |
2009年 | 569篇 |
2008年 | 623篇 |
2007年 | 615篇 |
2006年 | 590篇 |
2005年 | 462篇 |
2004年 | 399篇 |
2003年 | 381篇 |
2002年 | 311篇 |
2001年 | 278篇 |
2000年 | 230篇 |
1999年 | 186篇 |
1998年 | 190篇 |
1997年 | 182篇 |
1996年 | 158篇 |
1995年 | 155篇 |
1994年 | 145篇 |
1993年 | 134篇 |
1992年 | 106篇 |
1991年 | 123篇 |
1990年 | 104篇 |
1989年 | 77篇 |
1988年 | 84篇 |
1987年 | 78篇 |
1986年 | 89篇 |
1985年 | 104篇 |
1984年 | 95篇 |
1983年 | 73篇 |
1982年 | 81篇 |
1981年 | 66篇 |
1980年 | 51篇 |
1979年 | 32篇 |
1978年 | 33篇 |
1977年 | 29篇 |
1976年 | 17篇 |
1973年 | 9篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
《Survey of ophthalmology》2023,68(5):920-928
There remains limited agreement regarding the efficacy and safety of different antivascular endothelial growth factor (anti-VEGF) agents for the management of polypoidal choroidal vasculopathy (PCV). Our meta-analysis compares different anti-VEGF agents for PCV treatment. Ovid MEDLINE, EMBASE, and Cochrane Library were systematically searched from January 2000 to July 2022. We included articles comparing the efficacy and safety of different anti-VEGF agents, specifically bevacizumab (BEV), ranibizumab (RAN), aflibercept AFL), and brolucizumab (BRO), for patients with PCV. 10,440 studies were identified, 122 underwent full-text review, and seven were included. One study was a randomized trial, and six were observational studies. Ranibizumab and aflibercept were associated with a similar best-corrected visual acuity (BCVA) at the last visit in three observational studies (P = 0.10), similar retinal thickness at the last visit in two observational studies (P = 0.85). One observational study comparing BEV versus RAN found comparable outcomes for final BCVA, retinal thickness, and polyp regression. One randomized trial on BRO versus AFL found comparable outcomes for improvement in BCVA, while anatomical outcomes favored BRO. The available evidence suggests that final BCVA is comparable across different anti-VEGF agents, however, further investigation is warranted due to paucity of evidence. 相似文献
2.
3.
4.
5.
6.
《Diagnostic Histopathology》2022,28(3):142-148
Adenoid cystic carcinoma (AdCC) is a salivary gland-type of cancer that may also occur in the breast. Breast AdCC shows the same morphological spectrum as is observed in salivary glands, with recognition of individual subtypes that may differ in their clinical behaviour. AdCC classic variant (C-AdCC) is a slowly growing tumour, with a low rate of axillary node and distant metastases. Local recurrences may develop as a consequence of incomplete surgical excision. C-AdCC should be differentiated from the solid-basaloid variant of AdCC (SB-AdCC) that is characterized by nuclear atypia, frequent mitotic figures and necrosis, in addition to the solid architecture. SB-AdCC is a more aggressive tumour, with higher rates of axillary node and distant metastases. AdCC may also co-exist with more aggressive types of carcinoma including metaplastic and neuroendocrine carcinoma, referred to as AdCC with high grade transformation (HG-AdCC). This paper reviews the key diagnostic criteria of the different subtypes of breast AdCC with emphasis on differential diagnosis and prognostic parameters. 相似文献
7.
Sounak Gupta Rafael E. Jimenez Loren Herrera-Hernandez Christine M. Lohse R. Houston Thompson Stephen A. Boorjian Bradley C. Leibovich John C. Cheville 《Mayo Clinic proceedings. Mayo Clinic》2021,96(6):1470-1489
ObjectiveTo study the clinical features and identify unique renal neoplasia subtypes and their prognostic implications in individuals with tuberous sclerosis complex (TSC).Patients and MethodsThe Mayo Clinic nephrectomy registry included 37 patients with TSC diagnosed between 1970 and 2018. Four additional patients were identified from the pathology consultation and autopsy files. All available renal tumors were further characterized using immunohistochemistry and fluorescence in situ hybridization. Clinicopathologic features and follow-up were obtained from the medical record. The American Association for Cancer Research Project GENIE registry was accessed using cBioPortal for molecular profiling of angiomyolipoma (AML).ResultsA total of 276 renal tumors from 41 patients were analyzed. Renal tumors were classified into 9 distinct morphological subtypes, with AML predominating (238 [86%]). Interestingly, all these tumors acted in a benign fashion except one renal cell carcinoma with clear cells and fibromyomatous stroma and one epithelioid AML that metastasized. Molecular profiling studies revealed that epithelioid AMLs were enriched for alterations of TP53, RB1, and ATRX. Eight patients died of direct complications of TSC, including 3 of end-stage renal disease. To date, none have died of a renal epithelial neoplasm.ConclusionThe identification of unique renal neoplasia subtypes may provide important clues to establish a diagnosis of TSC, and in the somatic setting, this finding has important implications for accurate prognostication. These tumors tend to be indolent, and only 2 of 276 tumors in our study exhibited metastatic behavior. Our results support multidisciplinary management with a focus on preservation of renal function. 相似文献
8.
9.
10.